The estimated Net Worth of Robert J Hugin is at least $142 Миллион dollars as of 3 October 2022. Mr. Hugin owns over 19,591 units of Biohaven Ltd stock worth over $812,594 and over the last 21 years he sold BHVN stock worth over $141,405,581. In addition, he makes $0 as Director at Biohaven Ltd.
Sign up
Mr. Hugin BHVN stock SEC Form 4 insiders trading
Robert has made over 84 trades of the Biohaven Ltd stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 19,591 units of BHVN stock worth $73,466 on 3 October 2022.
The largest trade he's ever made was exercising 744,400 units of Biohaven Ltd stock on 3 November 2014 worth over $10,682,140. On average, Robert trades about 50,792 units every 28 days since 2003. As of 3 October 2022 he still owns at least 22,749 units of Biohaven Ltd stock.
You can see the complete history of Mr. Hugin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Hugin biography
Robert J. Hugin serves as Director of the Company. Mr. Hugin joined Celgene in 1999 as Chief Financial Officer and served in positions of increasing responsibility during his 19-year tenure with the company, including Executive Chairman, Chief Executive Officer, President and Chief Operating Officer. Until his retirement in 2018, he was the Chairman of the Board of Directors, serving as Executive Chairman from 2016 to 2018. Under his leadership, Celgene saw unprecedented results across all facets of the company and grew by over $30 billion in market capitalization. He is a noted health expert, who advocated for the importance of business development collaborations, innovations in science and improved patient access. Mr. Hugin also serves as a Director of Chubb Limited, Member of the Board of Trustees of Princeton University and Chair of The Darden School Foundation, University of Virginia . Additionally, Mr. Hugin is currently Chair of the Board of the Garden State Initiative, a nonpartisan research and educational organization focused on economic issues in New Jersey . He is a longstanding Member of the Board of Trustees of Family Promise, a national non-profit network assisting homeless families, and Director of the Parker Institute for Cancer Immunotherapy. Mr. Hugin is past Chairman of the Boards of The Pharmaceutical Research and Manufacturers of America and the Healthcare Institute of NJ. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985. He also served as a United States Marine Corps infantry officer during the intervening period.
What's Robert Hugin's mailing address?
Robert's mailing address filed with the SEC is CHUBB BUILDING, 17 WOODBOURNE AVENUE, HAMILTON, D0, HM 08.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs и Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Mr. Hugin stock trades at Biohaven Ltd, Chubb и Danaher
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer